image
Healthcare - Medical - Diagnostics & Research - NASDAQ - CN
$ 3.75
1.35 %
$ 36.3 M
Market Cap
-0.49
P/E
1. INTRINSIC VALUE

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency.[ Read More ]

The intrinsic value of one BNR stock under the base case scenario is HIDDEN Compared to the current market price of 3.75 USD, Burning Rock Biotech Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BNR

image
FINANCIALS
537 M REVENUE
-4.58%
-669 M OPERATING INCOME
31.73%
-654 M NET INCOME
32.69%
-256 M OPERATING CASH FLOW
44.01%
-9.3 M INVESTING CASH FLOW
-24.61%
-48.8 M FINANCING CASH FLOW
43.38%
136 M REVENUE
7.89%
-111 M OPERATING INCOME
11.61%
-108 M NET INCOME
100.00%
-40.8 M OPERATING CASH FLOW
-1.56%
-227 K INVESTING CASH FLOW
90.49%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition Burning Rock Biotech Limited
image
Current Assets 884 M
Cash & Short-Term Investments 629 M
Receivables 168 M
Other Current Assets 87.8 M
Non-Current Assets 156 M
Long-Term Investments 337 K
PP&E 144 M
Other Non-Current Assets 11.4 M
Current Liabilities 263 M
Accounts Payable 18.1 M
Short-Term Debt 8.63 M
Other Current Liabilities 237 M
Non-Current Liabilities 8.23 M
Long-Term Debt 3.69 M
Other Non-Current Liabilities 4.54 M
EFFICIENCY
Earnings Waterfall Burning Rock Biotech Limited
image
Revenue 537 M
Cost Of Revenue 174 M
Gross Profit 363 M
Operating Expenses 1.03 B
Operating Income -669 M
Other Expenses -15.6 M
Net Income -654 M
RATIOS
67.59% GROSS MARGIN
67.59%
-124.54% OPERATING MARGIN
-124.54%
-121.63% NET MARGIN
-121.63%
-85.07% ROE
-85.07%
-62.85% ROA
-62.85%
-87.42% ROIC
-87.42%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Burning Rock Biotech Limited
image
Net Income -654 M
Depreciation & Amortization 133 M
Capital Expenditures -9.38 M
Stock-Based Compensation 261 M
Change in Working Capital -52.2 M
Others -9.98 M
Free Cash Flow -265 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Burning Rock Biotech Limited
image
BNR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Burning Rock Biotech Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision oncology, and Dizal, a global biopharmaceutical company focused on malignant tumors and immunological diseases, jointly announced that the companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through their collaboration, has been approved by the National Medical Products Administration (NMPA) of China. This marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China. globenewswire.com - 1 month ago
Burning Rock Announces Changes to Management and Board of Directors GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Leo Li as a director from the Company's board of directors (the “Board”) and as the Company's chief financial officer, effective September 27, 2024. globenewswire.com - 1 month ago
Burning Rock Reports Second Quarter 2024 Financial Results GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Business Updates Therapy Selection Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024. globenewswire.com - 2 months ago
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares GUANGZHOU, China, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and (b) to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List. As a result of sustained low volume of trading and liquidity in the ADSs on the LSE, and taking into account the costs associated with maintaining such listing in place, the Company is seeking the delisting and cancellation of admission to trading of the ADSs from the LSE (the “Delisting”). globenewswire.com - 2 months ago
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, on December 29, 2023, the Company was notified by NASDAQ that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price for the Company's American depositary shares (the “ADSs”) was below the minimum bid price of $1.00 per share for 30 consecutive business days. globenewswire.com - 5 months ago
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies. globenewswire.com - 5 months ago
Burning Rock Reports First Quarter 2024 Financial Results GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection and origin prediction. globenewswire.com - 5 months ago
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024 GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. globenewswire.com - 5 months ago
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024 GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary shares (the “ADS Ratio Change”) will become effective on May 15, 2024 (the “Effective Date”). For Burning Rock's ADS holders, the ADS Ratio Change will have the same effect as a one-for-ten reverse ADS split. globenewswire.com - 6 months ago
Burning Rock Publishes 2023 Annual Report on Form 20-F GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company's website at http://ir.brbiotech.com. globenewswire.com - 6 months ago
Burning Rock Announces ADS Ratio Change GUANGZHOU, China, April 26, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to become effective on or about May 15, 2024 (the “Effective Date”). globenewswire.com - 6 months ago
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, our OverC™ MCDBT also received the Breakthrough Device Designation by China's National Medical Products Administration (NMPA) in October 2023, making it the only test globally that has received Breakthrough Device Designation from both the FDA and the NMPA. globenewswire.com - 7 months ago
8. Profile Summary

Burning Rock Biotech Limited BNR

image
COUNTRY CN
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 36.3 M
Dividend Yield 0.00%
Description Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Contact No. 5, Xingdao Ring Road North, Guangzhou, 510005 https://www.brbiotech.com
IPO Date June 12, 2020
Employees 786
Officers Ms. Xiaozhi Hu Senior Director of Finance Dr. Zhihong Zhang Chief Technology Officer & Director Mr. Yusheng Han Founder, Chairman & Chief Executive Officer Mr. Hao Liu Senior Advisor